ALK and non-small cell lung carcinoma: The effect of anti‐PD‐1/PD‐L1 monoclonal antibody in NSCLC patients with epidermal growth factor/anaplastic lymphoma kinase (EGFR/ALK) mutation was poor, which was related to the simultaneous reduction in T effector lymphocytes in the tumor body under the influence of the mutation.147, 148, 149, 150